failure caused by isolated left ventricular (LV) noncompaction cardiomyopathy had been implanted with the Jarvik 2000 LV assist device 3 years previously as a bridge to survival and to decision via a left posterolateral thoracotomy, off-pump, with outflow graft anastomosis to the descending aorta and postauricular pedestal. The patient had an excellent postoperative course free of adverse events for 1.5 years. The pump was operated at a rotational speed of 9000 rounds per minute. Anticoagulation included acenocoumarol aiming for an international normalized ratio of 3 to 3.5 and 100 mg of aspirin daily.
On the 20th month of support, the patient presented with symptoms and signs of cardiogenic shock associated with a sudden increase in power consumption by the device. His international normalized ratio was 3.3, but during the previous week, his international normalized ratio was 2.2. Echocardiography revealed LV thrombus obstructing the pump inflow (the Figure, 
Figure.
A, A large mobile ellipsoid thrombus obstructing the pump inflow at the LV apex (red arrow). B, The beginning of fragmentation of the thrombus cap (yellow arrow) within 15 minutes from the onset of thrombolysis (yellow arrow) associated with immediate clinical improvement. C, A mobile crescent-shaped remnant of thrombus still attached to the device and the myocardium (orange arrow) at 90 minutes after thrombolysis. D, Complete resolution of thrombus at Ϸ120 minutes, after an additional intravenous infusion of 50 mg recombinant tissue plasminogen activator.
One repeated episode of thrombosis on the 23rd month of support was successfully treated with the same regimen. During a third episode, after partial thrombolysis and during heparin infusion, hemorrhagic shock resulting from a ruptured splenic hematoma was treated successfully with splenectomy and supportive therapy. Currently on the 31st month of support, the patient remains free of clinically evident episodes of thrombosis on the triple antithrombotic regimen.
Despite the recurrent thrombotic episodes, there was no clinically evident cerebrovascular accident or other site embolization. Outflow graft anastomosis to the descending aorta might be an important safety feature, and it may lessen the chances of cerebral embolization of pump thrombi. The design of the pump inflow (the triple-arch cage guarding the inflow) also seemed to be advantageous by restraining the entrance of large thrombus into the pump. Furthermore, the apical position of the device in the LV allowed an excellent echocardiographic window and facilitated close monitoring and titration of the dose of the thrombolytic regimen.
In conclusion, administration of intravenous thrombolysis under echocardiographic guidance is a feasible option for hemodynamically significant thrombosis of the Jarvik 2000 LV assist device. To the best of our knowledge, this is the first case of long-term support with the Jarvik 2000 in a patient with noncompaction cardiomyopathy and the first case of successfully treated recurrent thrombosis of the Jarvik 2000 with an intravenous thrombolytic regimen.
